Cargando…

Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program

BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Lukas, Schmid, Daniela, Kanitz, Elisabeth Eva, Zwazl, Ines, Pöllabauer, Eva, Jasinska, Joanna, Burgmann, Heinz, Kundi, Michael, Wiedermann, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328268/
https://www.ncbi.nlm.nih.gov/pubmed/30629620
http://dx.doi.org/10.1371/journal.pone.0210081
_version_ 1783386622649171968
author Richter, Lukas
Schmid, Daniela
Kanitz, Elisabeth Eva
Zwazl, Ines
Pöllabauer, Eva
Jasinska, Joanna
Burgmann, Heinz
Kundi, Michael
Wiedermann, Ursula
author_facet Richter, Lukas
Schmid, Daniela
Kanitz, Elisabeth Eva
Zwazl, Ines
Pöllabauer, Eva
Jasinska, Joanna
Burgmann, Heinz
Kundi, Michael
Wiedermann, Ursula
author_sort Richter, Lukas
collection PubMed
description BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-based intervention study. METHODS: The study period was divided into pre- (2009–2011) and post-period (2013–2017, February), regarding 2012 as transition year. Outcomes were defined as PCV10 ST-IPD, the PCV10-related ST 6A and 19A IPD and non-PCV10 excluding ST 6A-/19A-IPD (NVT-IPD). We used national surveillance data and compared average monthly incidence rate (IR) between pre- and post-period among <5, 5–49 and ≥50 years old. Additionally, for the 5–49 and ≥50 years old, and the 50–59 and ≥60 years old, we analyzed monthly incidence data of the pre-, post-period, and estimated trend and level changes by using a segmented time-series regression. RESULTS: The PCV-10 IPD was reduced by 58% (95% CI: 30%; 74%) and 67% (95% CI: 32%; 84%) among <5 and ≥50 years old; the reduction in ≥60 years was 71% (95% CI: 36%; 88%). There were no significant changes in the pre-post-rate or incidence trend of NVT-IPD in the <5 and ≥50 years old. ST-specific analyses revealed no ST 6A- and ST 19A IPD decline in any age-group, and a ST 8 IPD increase among ≥50 years old (IR ratio: 3.5; 95% CI: 1.7; 7.2). We found no vaccine effects among 5–49 years old. CONCLUSIONS: Our study adds to the evidence on direct and indirect protection of a childhood PCV10 vaccine program. Elderlies seem to benefit the most. Findings did not support PCV 10 cross-protection, but indicate replacement at least for ST 8 among the ≥50 years old. Follow-up analyses of IPD surveillance data are needed to fully characterize the magnitude of serotype replacement and further vaccine-attributable IPD reduction with time.
format Online
Article
Text
id pubmed-6328268
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-63282682019-02-01 Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program Richter, Lukas Schmid, Daniela Kanitz, Elisabeth Eva Zwazl, Ines Pöllabauer, Eva Jasinska, Joanna Burgmann, Heinz Kundi, Michael Wiedermann, Ursula PLoS One Research Article BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-based intervention study. METHODS: The study period was divided into pre- (2009–2011) and post-period (2013–2017, February), regarding 2012 as transition year. Outcomes were defined as PCV10 ST-IPD, the PCV10-related ST 6A and 19A IPD and non-PCV10 excluding ST 6A-/19A-IPD (NVT-IPD). We used national surveillance data and compared average monthly incidence rate (IR) between pre- and post-period among <5, 5–49 and ≥50 years old. Additionally, for the 5–49 and ≥50 years old, and the 50–59 and ≥60 years old, we analyzed monthly incidence data of the pre-, post-period, and estimated trend and level changes by using a segmented time-series regression. RESULTS: The PCV-10 IPD was reduced by 58% (95% CI: 30%; 74%) and 67% (95% CI: 32%; 84%) among <5 and ≥50 years old; the reduction in ≥60 years was 71% (95% CI: 36%; 88%). There were no significant changes in the pre-post-rate or incidence trend of NVT-IPD in the <5 and ≥50 years old. ST-specific analyses revealed no ST 6A- and ST 19A IPD decline in any age-group, and a ST 8 IPD increase among ≥50 years old (IR ratio: 3.5; 95% CI: 1.7; 7.2). We found no vaccine effects among 5–49 years old. CONCLUSIONS: Our study adds to the evidence on direct and indirect protection of a childhood PCV10 vaccine program. Elderlies seem to benefit the most. Findings did not support PCV 10 cross-protection, but indicate replacement at least for ST 8 among the ≥50 years old. Follow-up analyses of IPD surveillance data are needed to fully characterize the magnitude of serotype replacement and further vaccine-attributable IPD reduction with time. Public Library of Science 2019-01-10 /pmc/articles/PMC6328268/ /pubmed/30629620 http://dx.doi.org/10.1371/journal.pone.0210081 Text en © 2019 Richter et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Richter, Lukas
Schmid, Daniela
Kanitz, Elisabeth Eva
Zwazl, Ines
Pöllabauer, Eva
Jasinska, Joanna
Burgmann, Heinz
Kundi, Michael
Wiedermann, Ursula
Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title_full Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title_fullStr Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title_full_unstemmed Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title_short Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
title_sort invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the austrian national immunization program
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328268/
https://www.ncbi.nlm.nih.gov/pubmed/30629620
http://dx.doi.org/10.1371/journal.pone.0210081
work_keys_str_mv AT richterlukas invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT schmiddaniela invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT kanitzelisabetheva invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT zwazlines invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT pollabauereva invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT jasinskajoanna invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT burgmannheinz invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT kundimichael invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram
AT wiedermannursula invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram